Novo Nordisk and Pfizer are showing some desperation in their gloves-off tussle for the obesity-drug assets of Metsera.

Metsera currently has no products on the market, but is developing oral and injectable treatments for obesity and diabetes.

Pfizer has filed a lawsuit against Novo Nordisk and Metsera in an attempt to force through its takeover of the weight-loss drug developer and prevent Novo Nordisk from taking its rival bid forward.

A few years ago, Pfizer (NYSE: PFE) represented the ideal pharmaceutical stock investment. The company, as leader in the coronavirus vaccine and treatment market, offered a great deal of growth, and ...

Pfizer (PFE) could use its connections within President Donald Trump’s administration to try to best Novo Nordisk’s (NVO) rival bid to acquire U.S. obesity biotech firm Metsera (MTSR), Reuters’ ...

Elsewhere, the busy earnings season continues with reports due from several notable companies such as Advanced Micro Devices, Palantir (NASDAQ:PLTR), Robinhood, Super Micro Computer, Qualcomm, ARM ...

CNBC's Charlotte Reed will travel to Copenhagen to speak with Novo Nordisk's new CEO after a bumpy few months.

In a report released today, Florent Cespedes from Bernstein maintained a Buy rating on Novo Nordisk, with a price target of DKK540.00. The company’s shares closed yesterday at DKK324.94. Take ...

Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on Novo Nordisk today and set a price target of DKK600.00. The company’s shares closed yesterday at DKK324.94. Take advantage of ...